Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $90.38 (market cap $41.29B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 5.6× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| IEF | SYRE | |
|---|---|---|
Market Cap | $41.29B | $7.35B |
Volume | 11,588,563 | 1,624,631 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $108.92 |
52-Week Low | $88.92 | $22.18 |
Typical Hold Time | 108 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF trades at $89.71, up 0.31% with a bearish technical signal from moving averages and oscillators. The ETF shows flat support/resistance around $89-90. Recent dividend payments of $0.31-$0.33 provide income, but financial ratios are unavailable. Market sentiment reflects Treasury volatility amid rising yields and inflation concerns.
Outlook remains cautious due to persistent bond market pressures and macroeconomic uncertainty. Opportunities exist for income-focused investors via dividends, but risks include prolonged yield increases and geopolitical factors affecting fixed income. Monitor Federal Reserve policy shifts for directional cues.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
